Medical Equipment

Medlab Clinical Ltd (ASX:MDC) Executes Master Services Agreement with WEP Clinical Ltd

🕔7/23/2021 3:05:35 PM

Medlab Clinical Ltd (ASX:MDC), an Australian biotech using delivery platforms to enhance medicines is pleased to announce the execution of a Master Services Agreement with WEP Clinical Ltd for the exclusive development and delivery of Named Patient Programmes

Read Full Article

BTC Health Limited (ASX:BTC) Acquires Exclusive Distribution Rights for Bronchitol(R) and Aridol(R) from Pharmaxis

🕔7/6/2021 10:44:41 AM

BTC Health Limited (ASX:BTC) is pleased to announce its investee company, BioImpact Pty Ltd, has acquired exclusive distribution rights for specialty respiratory brands Bronchitol(R) and Aridol(R) from Pharmaxis (ASX:PXS) in Australia, New Zealand, Singapore, Malaysia, Hong Kong and South Korea (Bronchitol(R) only).

Read Full Article

AusCann Group Holdings Ltd (ASX:AC8) and CannPal Enter Into Scheme of Arrangement

🕔11/16/2020 12:10:39 PM

AusCann Group Holdings Ltd (ASX:AC8), an Australian based pharmaceutical company focused on the development, production and distribution of cannabinoid-based medicines within Australia and internationally, is pleased to announce that it has entered into a scheme implementation deed (SID) with CannPal Animal Therapeutics Limited.

Read Full Article

Cann Global Limited (ASX:CGB) Quarterly Activities and Cashflow Report

🕔8/3/2020 8:06:52 AM

Cann Global continued to drive sales throughout the quarter resulting in cash receipts from customers of $333k up 54.6% on the prior corresponding period, but lower than the prior quarter due to shipping delays and therefore delayed payment on contracted sales.

Read Full Article

Cann Global Limited (ASX:CGB) Entitlement Issue Update and Shortfall Notification

🕔7/28/2020 7:14:24 PM

Cann Global Limited (ASX:CGB) is pleased to confirm that the 1 for 4 renounceable entitlement offer announced on 3 July 2020 (Entitlement Offer), closed on Thursday 23 July 2020.

Read Full Article

Cann Global Limited (ASX:CGB) Rights Issue Update

🕔7/10/2020 4:52:02 PM

Cann Global Ltd (ASX:CGB) today confirms that its Directors and largest shareholders intend to participate in the rights issues announced on 3 July 2020.

Read Full Article

Cann Global Limited (ASX:CGB) Research Results Lead to Broader Auto-immune Research

🕔6/15/2020 10:11:11 AM

Cann Global Limited's (ASX:CGB) medical Cannabis research division, Medical Cannabis Research Group Pty Ltd (MCRG) entered into a research agreement to research the possibility of the use of cannabis in the treatment of autoimmune disease, specifically multiple sclerosis (MS).

Read Full Article